All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-03-20T14:46:57.000Z

U.S. FDA approves ponatinib plus chemotherapy for adult patients with newly diagnosed Ph+ ALL

Mar 20, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

Bookmark this article

On March 19, 2024, it was announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to ponatinib, a BCR::ABL1 tyrosine kinase inhibitor, plus chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).1,2 This approval is based on promising efficacy and safety outcomes from the III PhALLCON study (NCT03589326), which met its primary endpoint of minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.2

PhALLCON study

PhALLCON is a randomized, multicenter, open-label trial of ponatinib versus imatinib combined with low-intensity chemotherapy in adult patients with newly diagnosed Ph+ ALL. A total of 245 adult patients were randomized 2:1 to either ponatinib (n = 1,640) or imatinib (n = 81) arm. The key results were as follows1,2:

  • A significantly higher improvement in MRD-negative CR rate at the end of induction for the ponatinib versus imatinib arm, at 30% and 12%, respectively (p = 0.0004).
  • Similar safety profiles between the two arms, with no new safety signals reported.
  • The most common adverse events were hepatic dysfunction, arthralgia, rash and related conditions, headache, pyrexia, abdominal pain, constipation, fatigue, nausea, oral mucositis, hypertension, pancreatitis/elevated lipase, peripheral neuropathy, hemorrhage, febrile neutropenia, fluid retention and edema, vomiting, paresthesia, and cardiac arrhythmias.

The U.S. FDA has recommended a dose of 30 mg ponatinib orally once daily, reduced to a dose of 15 mg orally once daily when an MRD-negative CR is achieved at the end of induction. Ponatinib should be continued with chemotherapy for up to 20 cycles until loss of response or unacceptable toxicity.

Conclusion

This approval marks an important clinical development, providing adult patients in the US with the first and only targeted frontline treatment for Ph+ ALL.

  1. U.S. Food & Drug Administration. FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome. Published Mar 19, 2024. Accessed Mar 20, 2024.
  2. Business Wire. Takeda announces U.S. FDA approval of supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in adult patients with newly diagnosed Ph+ ALL. https://www.businesswire.com/news/home/20240319911372/en/Takeda-Announces-U.S.-FDA-Approval-of-Supplemental-New-Drug-Application-sNDA-for-ICLUSIG%C2%AE-ponatinib-in-Adult-Patients-with-Newly-Diagnosed-Ph-ALL. Published Mar 19, 2024. Accessed Mar 20, 2024.

Your opinion matters

HCPs, what is your preferred format for educational content on the ALL Hub?
5 votes - 57 days left ...

Related articles

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox